News | November 07, 2024
JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
He has 35+ years of experience in understanding of business and products, analytical ability, eye for detail and computer literacy and knowledge of recent trends.
The partnership emphasises the introduction of renewable, bio-based materials into existing plastic applications to help reduce fossil resource dependency
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
These initiatives signify a substantial boost to healthcare infrastructure across India, aligned with the Prime Minister’s mission of ensuring quality healthcare services nationwide
He has more than 25 years of experience in manufacturing across various industries including petrochemicals, engineering polymers, agrochemicals, organic, and inorganic intermediates
Infant Mortality Rate in Bihar came down from 42 to 27 in 2020, and in Jharkhand, from 34 to 25 in 2020
JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
Giri is currently the President (India Business & Emerging Markets) of Amneal Pharmaceuticals
WEF recognises company’s Bharuch manufacturing facility as a global manufacturing lighthouse
Subscribe To Our Newsletter & Stay Updated
